New drug given to patients with existing drugs did not cause cancer, claims GlaxoSmithKline
Dawn Medical Editor
London: The British pharmaceutical company ‘GlaxoSmithKline’ (GSK) has claimed that the results of the final trial of the blood cancer drug ‘Blenrep’ developed by the company have been encouraging. Before the final trial of the drug, in November 2022, the company said that the drug failed to produce the desired standard results in the first phase of the final trial. It is claimed that the results of the drug have been encouraging. During the final trial, Blenrep was given to 302 cancer patients along with other drugs, GSK said.
According to the company, the volunteers were given ‘Blenrep’ along with the drug pomalidomide and the steroid drug dexamethasone. The newly developed drug, given to patients with existing drugs, did not cause cancer. The company’s shares rose after the results of a blood cancer drug trial were described as encouraging, and experts hoped It is hoped that the above medicine would be further improved and the world would soon get a new medicine for blood cancer.
